SenesTech, Inc. (SNES)

Over the past six months, several events have impacted SenesTech, Inc.'s stock price. SenesTech reported a 43% year-over-year increase in Q3 2025 revenue, driven by its rodent birth control product. SenesTech announced the addition of the Belize Raptor Center as an official distributor of Evolve Rat Birth Control. Evolve is available on Lowes.com, suggesting an expanded distribution channel. SenesTech announced a CEO transition plan, with the board initiating a search for new leadership. Evolve was approved in New Zealand, further expanding the company's international market. As of February 5, 2026, the closing stock price was $1.78. The stock has experienced a decline of 35.60% between January 28, 2025 and January 27, 2026. Over the last year, SenesTech, Inc. has shown a -39.68% decrease. The 52-week high was $6.24 and the 52-week low was $1.30.

The provided search results do not contain explicit information about the demand seasonality for SenesTech, Inc.'s products and services. However, pest control, in general, can exhibit some seasonality depending on pest breeding cycles and activity, which might indirectly influence demand for SenesTech's fertility control products. The company's focus on proactive control with products like Evolve Rat suggests a potential for consistent demand beyond reactive pest management.

SenesTech, Inc. is a biotechnology company focused on developing and commercializing technology for managing animal pest populations through fertility control, offering a non-lethal approach to pest management. The company's primary products are ContraPest and Evolve. ContraPest is a liquid bait designed to make brown and black rats infertile. Evolve is a soft bait that uses cottonseed oil to limit the reproduction of male and female rats and mice. Evolve Rat, launched in early 2024, quickly became the company's top-selling product line, contributing approximately 52% of Q3 2024 revenue. Evolve Mouse, launched in May 2024, also significantly contributed to Q3 2024 revenue. SenesTech also provides teleconsulting and technical advisory services.

SenesTech, Inc. is headquartered in Phoenix, Arizona, United States. The company's products are used across the United States by pest management professionals in various settings. Internationally, SenesTech has expanded its reach, with distribution agreements for Evolve in 12 countries/territories. Commercial product shipments and approvals have occurred in Hong Kong, the United Arab Emirates, the Maldives, and the Netherlands. The company also secured market approval in New Zealand in February 2026, supporting New Zealand's Predator Free 2050 Initiative, and has signed exclusive agreements in Indonesia and the Philippines. Deployments are also expected in Australia later in the year, contingent on regulatory approvals.

SenesTech's brand reputation in the past year appears to be centered around its commitment to humane, effective, and sustainable pest control through fertility management. ContraPest has demonstrated sustained success in reducing rat populations. The successful launch and rapid adoption of Evolve Rat and Evolve Mouse have reinforced the company's innovative and environmentally responsible image. Securing approvals and distribution agreements in new international markets highlights the global recognition and acceptance of their fertility control solutions. The company's mission to provide effective pest management alternatives that are safe for people, pets, and the environment contributes positively to its brand image. No significant negative events impacting SenesTech's brand reputation in the past year were found in the search results.

SenesTech, Inc. has a diverse ownership structure. Institutional shareholders own 8.89% of the stock, while SenesTech insiders hold 77.61%, and retail investors account for 13.50%. Major institutional owners include Renaissance Technologies Llc, Sabby Management, Llc, and Vanguard Group Inc. Largest individual shareholders (insiders) include Grover T. Wickersham (23.74%), Kenneth S. Siegel (13.45%), and Loretta Powers Mayer (8.33%).